Literature DB >> 12702044

Barrett's esophagus: Macroscopic markers and the prediction of dysplasia and adenocarcinoma.

Lybus C Hillman1, Louise Chiragakis, Anthony C Clarke, Sunil P Kaushik, Graham L Kaye.   

Abstract

BACKGROUND AND AIMS: Surveillance endoscopy has been advocated for patients with Barrett's esophagus but the cost-effectiveness of this has been questioned. The aim of this study is to identify an optimum surveillance protocol by examining if macroscopic markers at diagnosis predict the development of dysplasia.
METHODS: The sample was 353 patients with Barrett's esophagus undergoing surveillance by a community-based group of gastroenterologists between 1981 and 2001. At diagnosis the presence of macroscopic and microscopic markers was noted. The presence and pattern of dysplasia and development of adenocarcinoma was documented during subsequent surveillance.
RESULTS: Three hundred and fifty-three patients (71% male) underwent regular surveillance over 19 056 patient-months (median 42 months), having a median number of three surveillance endoscopies (range 1-40). Nine patients (seven male) developed adenocarcinoma (1/176 patient years) and four male patients developed high-grade dysplasia (1/397 patient years). Twelve of these 13 patients entered with one or more macroscopic markers: severe esophagitis, nodularity, Barrett's ulcer or stricture. Dysplasia risk was associated with macroscopic markers. Patients who entered with one marker were 6.7 times more likely to develop high-grade dysplasia/adenocarcinoma (HR = 6.7, 95% CI = 1.3, 35). Patients who entered with two or more markers were 14 times more likely to develop high-grade dysplasia/adenocarcinoma (HR = 14.1, 95% CI = 2.02, 102).
CONCLUSIONS: The presence of severe esophagitis, Barrett's ulcer, nodularity or stricture at entry indicates a high-risk group for Barrett's esophagus. Cost-effectiveness of surveillance for these patients and those with dysplasia at entry would thus improve. Copyright 2003 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702044     DOI: 10.1046/j.1440-1746.2003.02965.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

Review 1.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

Review 2.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

Review 3.  Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative.

Authors:  Raf Bisschops; Miguel Areia; Emmanuel Coron; Daniela Dobru; Bernd Kaskas; Roman Kuvaev; Oliver Pech; Krish Ragunath; Bas Weusten; Pietro Familiari; Dirk Domagk; Roland Valori; Michal F Kaminski; Cristiano Spada; Michael Bretthauer; Cathy Bennett; Carlo Senore; Mário Dinis-Ribeiro; Matthew D Rutter
Journal:  United European Gastroenterol J       Date:  2016-08-21       Impact factor: 4.623

Review 4.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 5.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

Review 6.  Gender difference in gastro-esophageal reflux diseases.

Authors:  Kiyotaka Asanuma; Katsunori Iijima; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

7.  Predictors of dysplastic and neoplastic progression of Barrett’s esophagus

Authors:  Saleh Alnasser; Raman Agnihotram; Myriam Martel; Serge Mayrand; Eduardo Franco; Lorenzo Ferri
Journal:  Can J Surg       Date:  2019-04-01       Impact factor: 2.089

Review 8.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

9.  Clinical Outcomes Based on the Timing of Appearance of Visible Lesions in Barrett's Esophagus During Endoscopic Eradication Therapy.

Authors:  Prashanthi N Thota; Tanmayee Benjamin; Madhusudhan R Sanaka; John R Goldblum; John Vargo; Sunguk Jang; Rocio Lopez
Journal:  J Clin Gastroenterol       Date:  2020-02       Impact factor: 3.174

10.  Surveillance in Patients With Barrett's Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Yao Qiao; Ayaz Hyder; Sandy J Bae; Wasifa Zarin; Tyler J O'Neill; Norman E Marcon; Lincoln Stein; Hla-Hla Thein
Journal:  Clin Transl Gastroenterol       Date:  2015-12-10       Impact factor: 4.488

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.